Academy of Clinical Laboratory Physicians and Scientists

Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster

Retrieved on: 
Wednesday, September 7, 2022
The Retreat, Technology, Safety, Risk, Medtech, Board of directors, Health, Hub, U.S. Securities and Exchange Commission, Genolier Swiss Medical Network SA, Electron capture, Twitter, Academy of Clinical Laboratory Physicians and Scientists, Delegate, Patient, Philosophy, Time, Board, SEC, SIX Swiss Exchange, Industry, Cyberknife, Security (finance), NASDAQ, Ageing, R, Radiation, Lists of diseases, LinkedIn, Investment, Hospital, Faculty, Scientist, Clinique, Neoplasm, Private Securities Litigation Reform Act, YouTube, SWX, Heart, Education, Pharma, Paola Lattus, List of life sciences, Annual report, Ohio bioscience sector, Forward-looking statement, Pharmaceutical industry, Medical imaging, Facebook, Physician

SUNNYVALE, Calif., Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care. Genolier Innovation Hub will unite companies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster. The Hub is expected to open in early 2024.

Key Points: 
  • Genolier Innovation Hub will unitecompanies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster.
  • Genolier Innovation Hub will be located in the heart of the Genolier Healthcare Campus in Genolier, Switzerland.
  • "We are proud to lead the radiation therapy industry as an anchor for Genolier Innovation Hub.
  • "We look forward to partnering with Genolier Innovation Hub to usher in a new level of collaboration that speeds the progress made in patient-centric care.

Pattern Bioscience Appoints Carey-Ann Burnham as Chief Clinical Officer

Retrieved on: 
Thursday, March 10, 2022
Software, Research, Pharmaceutical, Hardware, Medical Devices, Technology, Infectious Diseases, Clinical Trials, Science, Biotechnology, FDA, Health, Microbiology, Single-cell analysis, European Journal of Clinical Microbiology & Infectious Diseases, Pathology, Barnes-Jewish Hospital, Risk, Wellcome Trust, Partnership, Infection, Leadership, Pneumonia, Machine learning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Washington University School of Medicine, Research, Physician, Pediatrics, Health, American Society for Clinical Pathology, Society, Journal, Sale, Sepsis, Doctor of Philosophy, Patient, List of life sciences, Cooperative, Digital, Technology, Academy, Academy of Clinical Laboratory Physicians and Scientists, Hospital-acquired infection, Internet, Food, Medicine, CEO, Epidemiology, Medical device, Pharmaceutical industry, Vaccine

Pattern Bioscience, Inc., developer of Digital Culture technology for rapid, direct-from-specimen pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST), announced the appointment of Carey-Ann Burnham, PhD, as chief clinical officer, effective March 30, 2022.

Key Points: 
  • Pattern Bioscience, Inc., developer of Digital Culture technology for rapid, direct-from-specimen pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST), announced the appointment of Carey-Ann Burnham, PhD, as chief clinical officer, effective March 30, 2022.
  • Dr. Burnham is a well-known and highly respected leader and investigator in the clinical microbiology and infectious disease space.
  • Dr. Burnham has also held several leadership roles in clinical microbiology, including serving as an editor for the Journal of Clinical Microbiology and as co-editor in chief for the upcoming 5th edition of the Clinical Microbiology Procedures Handbook.
  • This is a pivotal time for Pattern Bioscience as we move our Pneumonia Action Panel into the clinical phase, and Im thrilled to welcome Carey-Ann to the team, said Nick Arab, co-founder and CEO of Pattern Bioscience.

Leading Healthcare Software Provider, Provation, Announces New Pathology Partnership with ACL Laboratories

Retrieved on: 
Thursday, August 26, 2021
Aurora, Center, College, Centers for Medicare & Medicaid Services, Twitter, Colon, CLIA, Communication, GLOBE, American Board of Commissioners for Foreign Missions, CMS, Physician, College of American Pathologists, Telehealth, Doctor of Philosophy, Medicare, Flow cytometry, EHR, Academy of Clinical Laboratory Physicians and Scientists, Software as a service, Marie Cassidy, Heart, Clinical Laboratory Improvement Act, 1988, Hospital, Partnership, Solution, Laboratory, LinkedIn, Documentation, Information technology, List of pathologists, Esophageal cancer, Bloomberg L.P., Provat Lakra, COVID-19, ACL, Apex, MD, Medical device, Medical imaging, Medicine

This new partnership adds to a growing list of major pathology vendors that have invested in integration with Provation solutions.

Key Points: 
  • This new partnership adds to a growing list of major pathology vendors that have invested in integration with Provation solutions.
  • Provation is thrilled to have ACL Laboratories as an official pathology partner, said Brandon Hoheisel , Director of Strategic Partnerships at Provation.
  • Provation is a leading provider of healthcare software and SaaS solutions for clinical productivity, care coordination, quality reporting, and billing.
  • With over 90 pathologists board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology or both, Great Lakes Pathologists, S.C. and Midwest Diagnostic Pathology, S.C. deliver unsurpassed pathology services.